See more : Dixie Lee International Industries, Inc. (DLII) Income Statement Analysis – Financial Results
Complete financial analysis of 89bio, Inc. (ETNB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 89bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China South City Holdings Limited (1668.HK) Income Statement Analysis – Financial Results
- Pinterest, Inc. (PINS) Income Statement Analysis – Financial Results
- Gas Malaysia Berhad (5209.KL) Income Statement Analysis – Financial Results
- Bausch + Lomb Corporation (BLCO.TO) Income Statement Analysis – Financial Results
- China Overseas Land & Investment Limited (CAOVF) Income Statement Analysis – Financial Results
89bio, Inc. (ETNB)
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| Gross Profit | -273.00K | -240.00K | -79.00K | -60.00K | -17.00K | -6.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 122.23M | 80.80M | 70.33M | 36.20M | 21.35M | 13.68M |
| General & Administrative | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Other Expenses | 0.00 | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Operating Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Cost & Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Interest Income | 0.00 | 2.16M | 148.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.59M | 1.92M | 674.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| EBITDA | -134.46M | -99.85M | -90.19M | -49.50M | -57.19M | -16.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.20M | 102.25M | -89.74M | -49.36M | -26.64M | -15.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.88M | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Income Before Tax | -138.32M | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.87M | 19.00K | -147.00K | -59.00K | 218.00K | 28.00K |
| Net Income | -142.19M | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| EPS Diluted | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Weighted Avg Shares Out | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
| Weighted Avg Shares Out (Dil) | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations
In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). SVB Leerink views these results as 'strong' and says they provide a clear win for the company as.
89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia
89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). Hypertriglyceridemia is characterized by high triglycerides (TG) levels, a type of fat, in the bloodstream.
89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022
SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic...
89bio Pulls Back With Market — But Could The Stock Soar 250%?
89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%. In May, a number of analysts weighed in on 89bio following the biopharmaceutical company printing...
89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate...
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate...
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021
Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation...
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate...
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to...
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -
Source: https://incomestatements.info
Category: Stock Reports